Celtaxsys
is a clinical stage drug development company focused on developing novel therapies for inflammatory diseases... Read moreCeltaxsys
is a clinical stage drug development company focused on developing novel therapies for inflammatory diseases... Read more
News
Oct 11, 2018
Benzinga
Celtaxsys: Data from Celtaxsys' Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference
Oct 07, 2018
BioPortfolio
Celtaxsys: Celtaxsys Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250
Aug 02, 2018
Reuters
Celtaxsys: Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study
Aug 02, 2018
BioCentury
Celtaxsys: Celtaxsys planning Phase III program for CF candidate
Jul 29, 2018
BioPortfolio
Celtaxsys: Celtaxsys Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13042018 Prices from USD $250
May 17, 2018
PharmiWeb
Celtaxsys: Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July
Mar 08, 2018
BioPortfolio
Celtaxsys: Celtaxsys Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 27022018 Prices from USD $250
Feb 01, 2018
GlobeNewswire
Press Release: Celtaxsys : Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines
Jan 04, 2018
GlobeNewswire
Press Release: Celtaxsys : Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities
Jan 04, 2018
EconoTimes
Press Release: Celtaxsys : Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities
Celtaxsys Competitors
1
2
3
4
5
6
7
8
9
10